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CYP19A1, or human aromatase catalyzes the conversion of androgens to estrogens in a three-step
reaction through the formation of 19-hydroxy and 19-aldehyde intermediates. While the ﬁrst two
steps of hydroxylation are thought to proceed through a high-valent iron-oxo species, controversy
exists surrounding the identity of the reaction intermediate that catalyzes the lyase and aromatiza-
tion reaction. We investigated the kinetic isotope effect on the steady-state turnover of Nanodisc-
incorporated human CYP19A1 to explore the mechanisms of this reaction. Our experiments reveal
a signiﬁcant (2.5) kinetic solvent isotope effect for the C10–C19 lyase reaction, similar to that of
the ﬁrst two hydroxylation steps (2.7 and 1.2). These data implicate the involvement of Compound
1 as a reactive intermediate in the ﬁnal aromatization step of CYP19A1.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The catalytic cycle of cytochrome P450 has evolved after the
characterization of key intermediates involved in the hydrogen
abstraction and substrate hydroxylation by P450cam [1,2] as
depicted in Fig. 1.
Binding of the substrate molecule to cytochrome P450 [1]
partially or completely displaces the water molecule on the sixth
coordination site of the heme iron and causes a shift from a
hexa-coordinated low-spin complex to a penta-coordinated high-
spin ferric state [2], thereby resulting in an increase in redox
potential (by 100–130 mV) and facilitating the ﬁrst electron trans-
fer from its redox partners. Binding of molecular oxygen to the fer-
rous protein [3] generates the ferrous oxygenated (oxy-ferrous)
state [4], a key intermediate in P450 catalysis. The availability of
a second electron to the oxy-ferrous intermediate from the redox
partner yields the ‘‘peroxo anion’’ state [5a]. Proton transfer to
the distal oxygen atom orchestrated by the active site acid-alcohol
pair and bound water molecules results in formation of the
‘‘hydroperoxo’’ state [5b]. Each of these peroxo states may undergoa non-productive release of peroxide, regenerating the ferric form
of the enzyme (depicted as gray lines in Fig. 1). Alternatively, a sec-
ond protonation of the distal oxygen may occur which reduces the
O–O bond order resulting in cleavage, release of a water molecule
and generation of a higher valent metal-oxo species referred to as
‘‘Compound 1’’ (Cpd 1) [6] which then generates the hydroxylated
substrate.
Human aromatase (CYP19A1) is amembrane-boundmicrosomal
P450 that catalyzes the three-step conversion of androgens (andro-
stenedione, testosterone and 16-a-hydroxytestosterone) to estro-
gens (estrone, 17-b-estradiol and estriol, respectively) utilizing
three molecules each of NADPH and dioxygen per estrogen mole-
cule. The reaction proceeds through two intermediates, 19-hydroxy
(step I) and 19-aldehyde (step II) compounds, followed by the aro-
matization (step III) of ring A in the same active site (Fig. 2) [3–8].
CYP19A1 also proceeds through the same typical P450 cycle as
depicted in Fig. 1, where the hydroxylation during the step I and II
reactions are believed to proceed through the conventional high-
valent FeIV–O porphyrin cation radical, Cpd 1 [6], characteristic of
most P450s. During these steps, the acid-alcohol pair, Thr310 and
Asp309 conserved in the I-helix of CYP19A1 along with active site
water molecules play an important role in protonating the distal
oxygen atom of the peroxo anion to facilitate O–O bond cleavage
and generate Cpd 1, as described in P450cam and human CYP17A1
[9–14]. However, there has been a considerable debate for the
Fig. 1. Cytochrome P450 catalytic cycle.
Fig. 2. Three-step sequential oxidation of steroid catalyzed by human CYP19A1.
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two hypotheses have been proposed. In the ﬁrst postulated mecha-
nism, Cpd 1 is the key reactive species. Aromatization results from
C10–C19 scission of 19-oxo-AD intermediate and subsequent
release of C19 as formic acid, initiated by 1b-hydrogen abstraction
of A-ring of the steroid molecule by Cpd1 [15–17]. Alternatively,
the direct involvement of nucleophilic peroxo-ferric intermediate
with the substrate’s aldehyde functionality resulting in the decom-
position of peroxo hemiacetal intermediate to yield the observed
products has also been proposed [18].
Itwas shownearlier that inAD-boundCYP19A1 theﬁrst interme-
diate that accumulates during the low temperatureoxygenationand
subsequent cryoreduction experiment is an unprotonated peroxo-
ferric heme [19]. This suggested that the proton delivery pathway
is more hindered in CYP19A1 in the presence of AD. AD, however,
is the substrate for the hydroxylation step of CYP19A1. 19-oxo-AD,
the substrate for the lyase step of CYP19A1 was not investigated in
this study. The involvement of peroxo-ferric species as the reactive
intermediate has also been suggested in CYP2B4, CYP51 andCYP17 for C–C cleavage reactionswith aldehyde- or ketone-contain-
ing substrates [20–23], and by nitric oxide synthase [24]. Applica-
tion of density functional theory on a minimal CYP19A1 active site
showed an energetic preference for Cpd 1-mediated hydrogen
abstraction from the C1 of 19-aldo AD leading to estrone formation
rather than direct reaction of the peroxo-ferric species with 19-aldo
AD [17]. Importantly, it has beenhypothesized that the carbonylpair
(Thr310-Ala306) of CYP19A1and the catalyticwatermolecule could
also be responsible for the H2b abstraction of the 2,3-enolization
processes during the aromatization step, in which the acid-alcohol
pair Asp309 directly participate [7], unlike the indirect role of
Asp251 and Glu244 in hydroxylation by P450cam and P450eryF,
respectively [12]. Recently, Mak et al. characterized the oxy-com-
plexes of AD- and 19-oxo-AD bound CYP19A1 using resonance
Raman (rR) spectroscopy and foundno difference in the rR signature
of these two complexes. Their data also suggested the presence of a
H-bonding interaction to the terminal oxygen atom of the Fe–O–O
fragment for both cases, implying the involvement of Cpd 1 in both
reactions [25]. Therefore, the involvement of reactive intermediates
during the ﬁnal stage of aromatization in the ring A of androgens by
human CYP19A1 remains controversial and lacks an unambiguous
conclusion for the C10–C19 lyase reaction.
Herein, we report investigation of kinetic solvent isotope
effects (KSIEs) on the steady-state turnover of the hydroxylation
(steps I and II) and lyase (step III) reactions by human CYP19A1.
This technique has been shown to be useful in quantitating the
consecutive proton-transfer processes, involved in generating
the high-valent iron-oxo species [6] [26]. Therefore, the effect
of deuterium substitution on the catalytic rates can provide an
important indication of the number and identity of protons
involved in O–O bond heterolysis [13]. As a result, either the
involvement of Cpd 1, which depends on at least two protons
to generate the oxoferryl intermediates ([5a]? [5b]? [6]), or
nucleophilic reactivity of a ferric peroxoanion intermediate before
involvement of the proton in O–O bond cleavage could be sug-
gested, as was recently demonstrated for human CYP17A1 [23].
Although several steady-state parameters for the conversion of
AD to estrone have beenmeasured earlier either in human placental
aromatase [6,27–29], recombinant human CYP19A1 expressed in
insects [30,31] or bacteria [32–34], the transient-state kinetic stud-
ies during the conversion of AD to estrone have not been studied
except by the Guengerich group [34]. However, all previous kinetic
studieswere performed in detergent solubilized-form and reconsti-
tuted with different stoichiometries of CPR, and the detailed mech-
anism of the lyase reaction was not addressed. In this study, we
employed recombinant humanCYP19A1 incorporated inNanodiscs,
whichprovides a soluble, homogenous,monodispersedproteinwith
well controlled stoichiometry during reconstitution with its redox
partner CPR and hence mimics the biological integrity in the mem-
brane [35–37].2. Materials and methods
2.1. Human CYP19A1 expression, puriﬁcation and Nanodisc
incorporation
The expression and puriﬁcation of CYP19A1 and cytochrome
P450 oxidoreductase (CPR) was performed as described [19,38].
The self assembly of CYP19A1 Nanodiscs was performed as
described [37].2.2. NADPH oxidation
Incorporation of CPR into preformed and puriﬁed human
CYP19A1 Nanodiscs was made by direct addition of oligomeric
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described [39]. Brieﬂy, 1 ml of CYP19A1 and CPR solution in
100 mM potassium phosphate buffer, pH 7.4, containing 50 mM
NaCl and 50 lM substrate (AD, 19-OH-AD, or 19-Oxo-AD) was
brought to 37 C in a stirred quartz cuvette, path length of
0.4 cm. The sample was incubated for 3 min and the reaction was
initiated by addition of 300 lM of NADPH. The consumption of
NADPH was monitored by recording the absorbance at 340 nm
for 10 min. The reaction was stopped by adding 50 ll of 9 M sulfu-
ric acid to bring the pH below 4.0. The sample was removed from
the cuvette, ﬂash frozen in liquid nitrogen, and stored at 80 C
until product analysis. The optical measurements were performed
on Hitachi U-3300 spectrophotometer supplied with temperature
controller and built-in magnetic stirrer. The rate of NADPH oxida-
tion was determined from the slope of absorption at 340 nm dur-
ing the ﬁrst three minutes using an extinction coefﬁcient of
6.22 cm1mM1. A ratio of 1:4 of P450:CPR was chosen based on
previously established optimal ratio of reductase to P450 for
in vitro turnover experiments using the Nanodisc system [39]. In
this approach the reductase, in a dynamic equilibrium with reduc-
tase molecules in solution, inserts into the P450 containing Nano-
disc through its membrane anchoring tail thereby allowing the
formation of an efﬁcient electron transfer complex.
2.3. Catalytic turnover
The conversion of AD, 19-OH and 19-oxo-AD to estrone was
analyzed by HPLC (Waters). Brieﬂy, 1 ll of 18 mM progesterone
solution in methanol was added to 1 ml each of the reaction sam-
ple, as an internal standard, and vortexed for 30 s. 2 ml of chloro-
form was added to each aliquots and vortexed for 30 s. The
organic phase was removed and dried under the stream of nitro-
gen. The dried sample was dissolved in 100 l of methanol and 30
l was injected onto C18-HPLC column, using a 150  2.1 mm,
3 lm (ACE-111-1502) with the mobile phase of 45% each of meth-
anol and acetonitrile in water and a ﬂow rate of 0.2 ml/min. The
19-hydroxylated and 19-Oxo product of AD was separated in the
linear gradient of methanol and acetonitrile from 20% to 80% in
30 min, and detected at 240 nm. The formation of estrogen was
detected at 280 nm. Peak integration was performed with GRAM/
32 software (Thermo Fischer Scientiﬁc).
3. Results and discussion
3.1. Steady-state kinetic turnover by CYP19A1 in protiated and
deuterated solvent systems
CYP19A1 and CPR self-assembled in Nanodiscs was used to
quantitate product formation and NADPH oxidation rates in the
presence of saturating concentrations of AD and 19-OH-AD for
hydroxylation and 19-oxo-AD for the lyase reaction at 37 C andFig. 3. Time dependent total conversion of AD (A),pH/pD 7.4. Deuterated samples were prepared by exhaustive
exchange of the proteins in corresponding D2O buffers.
In order to determine the reaction time for the substrates AD,
19-OH-AD and 19-oxo-AD, ﬁrstly time-dependent substrate con-
version was performed and the 10 min incubation time was chosen
for the catalytic activity, during which the catalytic activity was in
linear phase (Fig. 3).
Using AD as the starting substrate, 19-OH-AD and 19-oxo-AD
were detected in the reaction mixture under steady state
conditions. Similarly, 19-oxo-AD and estrone were obtained
when 19-OH-AD was used as the starting substrate for turnover
experiments. Starting with AD, 19-OH-AD and 19-oxo-AD
were obtained with the individual rates of 1.63 ± 0.04 min1 and
4.06 ± 0.30 min1, respectively, (total rate of 5.70 ± 0.34 min1)
when the reaction was carried out in a protiated buffer system.
Rates of formation of both these products showed substantial
slowing upon H/D substitution, yielding a KSIE for the step-I
hydroxylation reaction of kH/kD = 2.7. In both the cases, the rate
of second product formation was almost 2.5 times faster, suggest-
ing a distributive nature of the enzyme. It is noteworthy that both
the rates of formation of individual products (0.62 ± 0.07 min1
and 1.52 ± 0.15 min1 for 19-OH-AD and 19-oxo-AD, respectively)
as well as total product (2.14 ± 0.22 min1), displayed an isotope
effect of P2.6 (Fig. 4A).
These KSIE data are very similar to the reported values for other
well studied P450 systems catalyzing hydroxylation chemistry
[13,40,41]. This was expected since the ﬁrst two steps of CYP19A1
catalysis i.e. AD to 19-OH-AD and 19-OH-AD to 19-oxo-AD are
standard P450 hydroxylations and are thought to go through the
classical Cpd 1 mediated H-rebound mechanism [42].
When 19-oxo-AD was used as the C10–C19 lyase substrate, the
rate of estrone formation was 2.5 times slower in D2O (i.e.
7.1 ± 0.8 min1 in H2O versus 2.8 ± 0.8 min1 in D2O) (Fig. 4C). This
corresponds to the KSIE of kH/kD = 2.53, similar to that seen when
AD was used as the starting substrate. This suggests the involve-
ment of same reactive intermediate Cpd 1 during catalysis. In con-
trast, the involvement of unprotonated peroxo-ferric intermediate
in the catalysis of C17–C20 lyase step by CYP17A1 resulted in a
large inverse solvent isotope effect kH/kD = 0.4 arising from compe-
tition between catalysis through a proton-independent intermedi-
ate, viz. the peroxo anion, and uncoupling via proton-dependent
uncoupling pathway(s), viz. the peroxide and the oxidase shunt
[23].
The conversion of 19-OH-AD to its products by CYP19A1 is unu-
sual. Use of 19-OH-AD, substrate for the second hydroxylation
step, as the starting substrate also yielded two products. In H2O,
19-oxo-AD and estrone were obtained at a rate of 2.3 ± 0.2 min1
and 1.8 ± 0.3 min1 respectively giving a total rate of 4.1 ±
0.5 min1. The second hydroxylation step of CYP19A1 also showed
the same distributive nature of the enzyme and gave two products.
However, the rate of second product formation was slower in this19-OH-AD (B) and 19-oxo-AD (C) by CYP19A1.
Fig. 4. Steady-state kinetic solvent isotope effects observed for hydroxylase (A and
B) and lyase (C) CYP19A1 catalysis. The number on the bar represents the value of
the activity. The error bar represents the standard deviation of 3–5 independent
measurements.
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2.39 ± 0.14 min1 and 0.91 ± 0.09 min1, respectively (the total of
3.30 ± 0.23 min1) in D2O, which gave an overall KSIE ofFig. 5. Conversion of 19-OH-AD to 19-oxo-AD by CYP19A1
Table 1
Rates of formation of CYP19 products and product intermediates in a reconstituted system
Product Substrate
19-OH AD
(min 1)
19-oxo-AD
(min 1)
Estrone
(min1)
Product 2/
product 1
AD 1.63 4.06 2.49
0.62 1.52 2.45
19-OH AD 2.30 1.80 0.78
2.39 0.91 0.38
19-oxo-AD 7.10 –
2.80 –
H2O/D2O.
Fig. 6. Comparison of the rates of NADPH oxidation (nmol NADPH/min/nmol p450) (solid
D2O (B). The error bar represents the standard deviation of 3–5 independent measuremkH/kD = 1.2 (Fig. 4B). Formation of estrone showed a KSIE of 2
(1.8 min1 in H2O versus 0.91 min1 in D2O). However, the forma-
tion of 19-oxo-AD showed no solvent isotope effect bringing the
net KSIE of product formation down to 1.2. Conversion of 19-OH-
AD to 19-oxo-AD goes through a hydroxylation at the C19 to
produce a gem-diol that then undergoes dehydration to yield the
19-oxo-AD intermediate (Fig. 5). It is plausible that the rate of
dehydration of the gem-diol intermediate is partially rate limiting
resulting in a diminished KSIE for 19-oxo-AD formation and giving
rise to a smaller observed KSIE with respect to total product for
step II as compared to steps I and III of CYP19A1 catalysis. It is
noteworthy that the formation of estrone from 19-OH-AD shows
a KSIE >2, which is consistent with other data. Table 1 summarizes
the individual and total product formation rates using AD, 19-OH-
AD and 19-oxo-AD as starting substrates in protiated and deuter-
ated solvents.
3.2. NADPH oxidation rates
The overall rate of NADPH oxidation in the presence of various
substrates of CYP19A1 was also studied. The total rates of conver-
sion of AD and 19-OH in H2O are 37 ± 4.5 min1 and 37 ± 4 min1,
and in D2O are 14 ± 1.5 min1 and 8.00 ± 1.3 min1, respectively.going through dehydration of a gem-diol intermediate.
under steady state turnover conditions.
KSIE w.r.t
product 1
KSIE w.r.t
product 2
Total product
(min1)
Overall KSIE
2.6 2.7 5.69 2.7
2.14
1.0 2.0 4.10 1.2
3.30
2.5 7.10 2.5
2.80
bar) and coupling efﬁciency (%) (open bar) during CYP19A1 catalysis in H2O (A) and
ents.
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uct formation rate (Fig. 6). Though both the conversions were
highly uncoupled, the coupling efﬁciency was higher in D2O (16%
and 41%) compared to 15% and 11% in H2O for the substrates AD
and 19-OH-AD, respectively. Likewise, when the lyase substrate
19-oxo-AD was used, the rate of NADPH oxidation in D2O was also
decreased by 83%, from 35 ± 1 min1 to 6 ± 1.2 min1 (Fig. 6). A
higher level of coupling in deuterated solvents is due to slowing
of the proton dependent uncoupling pathways, predominantly
the peroxide and oxidase shunt pathways. The higher coupling efﬁ-
ciency observed in the presence of 19-OH-AD and 19-oxo-AD may
be attributed to the polar nature of these substrates thereby mak-
ing possible presence of additional water molecules and/or
enhanced stabilization of the existing hydrogen-bonding network
at the active site of the enzyme.
4. Conclusion
We observe a normal slowing of steps 1 and 2 of CYP19A1 catal-
ysis (kH/kD of 2.7 and 1.2) consistent with the need for two proton-
ation steps in concomitant formation of the hydroperoxo-ferric
complex and Cpd 1 in D2O. These observations are also consistent
with the previous reports of solvent isotope effects in P450cam and
other P450s [10,41–43]. The presence of kinetic solvent isotope
effect of a similar magnitude when 19-oxo-AD, the substrate for
lyase step of CYP19A1, suggests the involvement of the same
intermediate viz. Cpd 1 for the aromatization step of CYP19A1
as well. In addition, CYP19A1 also showed the highest coupling
for the lyase substrate, 19-oxo-AD, compared with the hydroxylase
substrates, AD and 19-OH-AD, in both protiated and deuterated
solvent system.
Taken together, our results suggest that the involvement of the
same high-valent iron-oxo species, Cpd 1, as the reactive interme-
diate during the conversion of AD, 19-OH-AD and 19-oxo-AD. This
is based on the signiﬁcant KSIE observed during the ﬁrst two steps
of hydroxylation as well as the last step of lyase reaction. Our con-
clusions are also in line with the suggestion, albeit indirect, of Cpd1
mediated C–C scission by CYP19A1 provided by the rR, character-
ization of the oxy-complexes of AD- and 19-oxo-AD bound
CYP19A1 in Nanodiscs. This suggestion of involvement of Cpd 1
during C10–C19 lyase reaction by CYP19A1 is in contrast to recent
observation of an inverse KSIE in human CYP17A1 involved in
androgen formation where the reactive peroxoanion intermediate
is involved in the catalytic step [23].
In conclusion, our results highlight the involvement of Cpd 1
during the ﬁrst two steps of aromatization by CYP19A1, a general
mechanism known to be involved in other P450s. We also impli-
cate the involvement of Cpd 1 as a reactive intermediate during
the controversial C10–C19 lyase reaction by human aromatase.
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